Podium to Practice: SABCS® 2025 – Primary results from ASCENT-07
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Studies / Trials Discussed
GS1-09 – Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07
Studies/trials discussed:
GS1-09 – Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.